



Motor Ocular Neuropathy Caused by Mefloquine

Suzana Kovačević^{1*}, Samir Čanović¹, Ana Didović Pavičić¹, Marija Škara Kolega¹, Ana Oštrić Brnjac¹ and Miro Morović²

¹Department of Ophthalmology, Zadar General Hospital, Zadar, Croatia

²Department of Infectious Diseases, Zadar General Hospital, Zadar, Croatia

Abstract

Mefloquine is widely used for prophylaxis and treatment of malaria. It can induce a range of neurological side effects and its' neurotoxic potential with neuron apoptosis and significant axonal degeneration was confirmed in several in vitro studies. We report a patient presented with rare symptoms of relapsing motor neuropathy involving extraocular muscles, primary *m. levator palpebrae*, occurring while the mefloquine treatment.

Keywords: Mefloquine; Malaria; Mefloquine toxicity; Ophthalmic neuropathy

Case Report

Mefloquine is an oral medication used for treatment and prevention of malaria [1]. Among subjects who received mefloquine for prophylaxis the most frequently observed side-effects are vomiting, dizziness, syncope, extrasystoles; among those who received the drug for treatment the most common adverse reactions are dizziness, myalgia, nausea, fever, headache, vomiting, diarrhea, skin rash etc. The most serious and permanent adverse side-effects observed were psychiatric disorders, sensorimotor peripheral neuropathy, vestibular imbalance and central nervous system disorders [2].

Experimentally it was found that neurological damages caused by mefloquine could be due to block of connexin molecules in the brain, the proteins that play role in movement, vision and memory [3,4]. More over, recently it was shown that mefloquine can cause axonal degeneration by disrupting the cellular redox environment which induce oxidative stress in nerve fibers [5,6].

A fifty-two year old male came for an examination with symptoms affecting upper lids. During more than last three years he suffered from intermittent attack of upper lids fasciculations, from few times a day to every one to two hours, every attack lasting for about twenty seconds. In the last year he also occasionally had cramps in upper lids, lasting for two to three seconds, several times a day. He had no visual acuity loss, no pathologic findings in ophthalmologic examination.

He went through the neurologic examination, EEG and MRI, with no pathologic findings. In his medical history we found out that the patient had recurrent attacks of tropical malaria, ten times during the last six years, as a result of working in an endemic area of malaria (Nigeria) for several years. During the last three years he was treated several times with mefloquine alone or sometimes with artemisinin, as a treatment option for semi-immune persons. He used the last dose of mefloquine 6 months prior to this examination. In the time he first noticed the symptoms, he was not using the therapy but few months prior to the onset. Since there were no other pathologic findings, ocular or general, and considering patient medical history, we concluded that the symptoms were mefloquine related. Therefore, we recommended mefloquine exclusion in the future and regular check-up to determine severity and reversibility of mefloquine damage. Follow-up during the next year showed no recurrence of ocular neuropathy.

Mefloquine is a 4-quinolonmethanol group drug. At prophylactic doses use, risk of serious toxicity is about 1 in 10,000 patients. Higher therapeutic doses associated usually with significantly higher rate of

CNS events (e.g. nausea, dizziness, fatigue, mental confusions and sleep loss); psychosis, encephalopathies and convulsions are seen in 1 in 1200-1700 patients [7].

There are documented cases of mefloquine toxicity on eyes, causing retinopathy and maculopathy, caused by tendency of the drug to accumulate in the retinal pigment epithelium and exert toxic effects [8,9].

As mentioned above, *in vitro* investigations explained the most frequent mechanisms of neuronal and axonal injury caused by mefloquine [3-6].

It is known that most antimalarial drugs (mefloquine, quinacrine, primaquine, chloroquine, amodiaquine) produce phototoxic cutaneous and ocular effects, including disturbances in skin pigmentation, corneal opacity, cataract formation and severe retinopathy [8]. In this regard, a case of severe maculopathy during the quinacrine prophylaxis [9]. Also, a case of sudden trigeminal sensory neuropathy affecting lips is described [10].

Our patient is presenting with symptoms of motor neuropathy involving extraocular muscles, upper lid retractors, primary *m. levator palpebrae* while using therapeutic doses of mefloquine.

Neuropathies have been documented in individuals taking mefloquine, but not involving extraocular muscles.

There were two reported cases of motor polyneuropathy, involving both upper and lower limbs, presented with skin changes (erythematous rash and dermatitis), with progressive weakness and inability to perform fine motor activities, after first exposure to mefloquine [2]. In both cases there was a full recovery without any residual deficit at the 3-month follow up.

To our knowledge this is the first case of extraocular muscles motor neuropathy in a patient treated with mefloquine.

***Corresponding author:** Suzana Kovačević, Zadar General Hospital, Bože Peričića, 523000 Zadar, Croatia, Tel: 00385-23-315677; Fax: 00385-23-312724; E-mail: suzana.kovacevic@zd.t-com.hr

Received May 15, 2014; **Accepted** October 20, 2014; **Published** October 30, 2014

Citation: Kovačević S, Čanović S, Pavičić AD, Kolega MŠ, Brnjac AO, et al. (2014) Motor Ocular Neuropathy Caused by Mefloquine. Gen Med (Los Angel) 2: 150. doi: [10.4172/2327-5146.1000150](https://doi.org/10.4172/2327-5146.1000150)

Copyright: © 2014 Kovačević S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.